Table 4.

Association of ODC genotypes with risk of adenoma recurrence stratified by aspirin treatment group, Aspirin/Folate Polyp Prevention Study, 1994–2001

RR (95% CI)a
SNPPlacebo81 mg/d Aspirin325 mg/d AspirinPint
rs130009160.89 (0.75–1.07)0.94 (0.76–1.15)0.84 (0.71–1.00)0.76
rs116949111.40 (1.06–1.85)1.24 (0.92–1.67)1.31 (1.00–1.70)0.82
rs24304190.91 (0.73–1.12)1.13 (0.89–1.42)1.27 (1.05–1.55)0.08
rs24304200.99 (0.82–1.20)1.21 (0.98–1.49)1.38 (1.15–1.66)0.05
rs109296691.26 (0.94–1.69)1.23 (0.92–1.66)1.21 (0.94–1.56)0.97
rs283624341.14 (0.91–1.44)0.83 (0.62–1.11)0.82 (0.65–1.04)0.10
rs8181620.94 (0.77–1.14)0.77 (0.61–0.98)0.84 (0.70–1.03)0.45
rs10495001.42 (0.99–2.05)1.53 (1.03–2.27)1.16 (0.75–1.80)0.63
rs283624160.63 (0.41–0.97)0.79 (0.51–1.25)1.19 (0.84–1.69)0.08
rs75599791.01 (0.84–1.22)1.15 (0.92–1.45)0.98 (0.82–1.18)0.50
rs283623800.75 (0.53–1.04)1.39 (1.02–1.87)1.03 (0.80–1.35)0.03
rs2302615b1.11 (0.91–1.36)0.94 (0.73–1.21)0.97 (0.79–1.19)0.56
rs17281480.88 (0.73–1.06)0.94 (0.76–1.15)0.93 (0.78–1.10)0.91
rs8858151.13 (0.91–1.40)0.86 (0.65–1.13)0.86 (0.69–1.09)0.19
rs28842110.95 (0.68–1.34)1.06 (0.74–1.52)1.06 (0.76–1.47)0.89
rs23575511.05 (0.86–1.28)1.15 (0.93–1.43)1.22 (1.02–1.46)0.56

Abbreviation: Pint = P for interaction (between aspirin treatment and genotype, modeled additively).

  • aPer-allele relative risk using an additive genetic model adjusted for age and sex.

  • bPreviously genotyped SNP (17).